Diseases of the Esophagus

Papers
(The median citation count of Diseases of the Esophagus is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
147. CHARACTERISTICS AND PREDICTORS OF EARLY POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER46
280. FEASIBILITY OF ROBOTIC-ASSISTED SURGERY FOR BENIGN ESOPHAGEAL LESIONS: SINGLE-CENTER EXPERIENCE35
321. ESD AND ELPS A NOVEL MINIMALLY INVASIVE TREATMENT FOR MULTI-EPISODE SUPERFICIAL ESOPHAGEAL SCC AND 2ND PRIMARY HYPOPHARYNGEAL SCC:A CASE REPORT33
538. A DECADE OF ESOPHAGEAL AND ESOPHAGO-GASTRIC JUNCTION CANCER EPIDEMIOLOGY IN NATIONAL CANCER INSTITUTE MEXICO29
523. RISK FACTORS ASSOCIATED WITH NOT RECEIVING ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA28
539. SURGICAL TECHNIQUES AND OUTCOMES OF GASTRIC CONDUIT RECONSTRUCTION FOLLOWING ESOPHAGECTOMY BY HAND-ASSISTED LAPAROSCOPIC SURGERY (HALS) FOR ESOPHAGEAL CANCER26
Pressure dynamics of the esophagogastric junction at rest and during inspiratory maneuvers after Nissen fundoplication25
158. PACLITAXEL PLUS CISPLATIN AND 5 FUOROURACIL INDUCTION CHEMOTHERAPY FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 3-YEAR SURVIVAL RESULT22
173. FEASIBILITY AND POTENTIAL ADVANTAGE OF ROBOT-ASSISTED ESOPHAGECTOMY FOR CT4B ESOPHAGEAL CANCER20
226. PHILOSOPHICAL CONSIDERATIONS IN SURGICAL INNOVATION18
245. CLINICAL UTILITY OF CTDNA IN LONGITUDINAL MONITORING OF TREATMENT RESPONSES AND RELAPSE IN METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA18
294. LEARNING CURVE OF MINIMALLY INVASIVE ESOPHAGECTOMY: OUR SERIES, SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS17
643. PRACTICAL IMAGING REVIEW OF EXPECTED FINDINGS AND POSSIBLE COMPLICATIONS RELATED TO MULTIMODAL TREATMENT OF ESOPHAGEAL CANCER16
Diagnostic differences in high-resolution esophageal motility in a large Mexican cohort based on geographic distribution15
570. ADRENAL METASTASES OF ESOPHAGEAL CANCER: SURGICAL MANAGEMENT OF SINGLE METASTASES15
327. ANALYSING THE ROLE OF PET-CT IN ESOPHAGEAL CANCER: A SINGLE CENTRE COHORT STUDY15
266. EXTENSION OF FDG-PET-BASED RADIOMIC MODELS ON IDENTIFICATION OF PATIENTS WITH RESIDUAL ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY15
411. SINGLE-PORT THORACOSCOPIC RESECTION FOR THE SPINDLE CELL TUMOR OF ESOPHAGUS15
239. EVALUATION OF SUBCARINAL LYMPH NODE DISSECTION AND METASTASIS IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY14
793. MODIFIED HELLER DOR FOR ACHALASIA14
408. COMPARISON OF THE SHORT-TERM EFFICACY OF THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY IN THE TREATMENT OF SPONTANEOUS ESOPHAGEAL RUPTURE14
803. 2-YEAR RESULTS IN ESOPHAGOGASTRIC JUNCTION CANCER TREATMENT13
594. TOTALLY MINIMALLY INVASIVE 2-STAGE ESOPHAGECTOMY VERSUS HYBRID 2-STAGE ESOPHAGECTOMY. A SINGLE CENTER EXPERIENCE13
765. PATTERNS, TIMING, AND SURVIVAL OF RECURRENCE FOLLOWING SURGERY FOR ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTRE ENSURE STUDY13
269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS13
Correction to: Radial incision and cutting for dilation before endoscopic submucosal dissection in patients with esophageal cancer on the distal side of severe benign esophageal strictures13
535. AUDITING THE PATIENTS OUTCOMES AFTER SURGERY FOR ESOPHAGEAL AND GASTRIC CARDIA CANCER WITHIN THE 18 YEARS PERIOD. SINGLE CENTER EXPERIENCE13
021. THE TOTALLY MECHANICAL COLLARD TECHNIQUE FOR CERVICAL ESOPHAGOGASTRIC ANASTOMOSIS REDUCES ANASTOMOTIC STRICTURE COMPARED WITH TRIANGULAR ANASTOMOSIS: A PROPENSITY SCORE-MATCHED STUDY12
461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL12
369. GENOMIC ALTERATIONS AND SURVIVAL AFTER TREATMENT OF EAC BY SURGERY WITHOUT CHEMO- OR RADIOTHERAPY12
739. SIGNIFICANCE OF COX2 INHIBITOR FOR ESOPHAGEAL CANCER FROM THE CLINICAL AND EXPERIMENTAL ESTIMATE12
118. USEFULNESS OF PERIOPERATIVE NUTRITIONAL THERAPY WITH THE GLUTAMINE/ARGININE/CALCIUM β-HYDROXY-β-METHYLBUTYRATE PRODUCT IN ESOPHAGEAL CANCER SURGERY11
167. A CASE REPORT: PERFORATION OF THE ESOPHAGUS CAUSED BY CHOPSTICKS11
159. AUDIT OF POSTOPERATIVE COMPLICATIONS ACCORDING TO PATHOLOGICAL RESPONSE AFTER TRIMODALITY THERAPY IN OESOPHAGEAL CANCER11
180. PROGNOSTIC INFLUENCE OF POSTOPERATIVE CRP LEVELS AFTER THORACOSCOPIC ESOPHAGECTOMY IN PATIENTS WITH ESCC11
107. CAMRELIZUMAB AND LOW-DOSE RADIOTHERAPY WITH CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (NICE-RT STUDY): PRELIMINARY RESULTS10
047. ASSOCIATION OF DIETARY FACTORS AND VOLATILE ORGANIC COMPOUNDS IN STOOL SAMPLES IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE10
287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY10
156. COMPARISON OF SHORT-TERM POSTOPERATIVE OUTCOMES BETWEEN HAND-ASSISTED LAPAROSCOPIC SURGERY AND LAPAROSCOPIC SURGERY FOR ABDOMINAL APPROACHES IN ESOPHAGEAL CANCER SURGERY10
237. IMPACT OF LYMPH NODE DISSECTION ON PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS UNDERGOING NEOADJUVANT CHEMOIMMUNOTHERAPY FOLLOWED BY RADICAL SURGERY10
297. COMPARING SURVIVAL AND COMPLICATION RATES IN CERVICAL VS. INTRATHORACIC ANASTOMOSIS FOR ELDERLY ESOPHAGEAL CANCER PATIENTS10
033. PERIOPERATIVE OUTCOMES OF ROBOT-ASSISTED ESOPHAGECTOMY: A 15-YEAR COMPARATIVE ANALYSIS OF 1401 CASES WITH OPEN AND VATS10
Novel histologic score predicts recurrent intestinal metaplasia after successful endoscopic eradication therapy9
The interventional esophagologist: tunneling a new way forward9
The broad impact of functional lumen imaging probe panometry in addition to high-resolution manometry in an esophageal clinical practice9
Modified reconstruction procedure in subtotal esophagectomy with retrosternal gastric pull up to reduce anastomotic leakage: a propensity score-matched analysis9
Patient-derived cancer organoids to tailor personalized treatment strategies in upper gastrointestinal malignancies9
092. COPING MECHANISMS FOR FINANCIAL TOXICITY AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN ESOPHAGEAL CANCER SURVIVORS9
Lymph node yield and its impact on survival outcomes: a retrospective multicenter cohort study from Denmark9
770. CLOSURE OF OESOPHAGEAL DEFECTS USING THE VACSTENT DEVICE: INITIAL INSIGHTS FROM THE LARGEST UK CASE SERIES9
207. THE EVOLUTION OF THE PERIOPERATIVE ENHANCED RECOVERY PROTOCOL IN ESOPHAGEAL SURGERY DURING 10 YEARS8
252. RIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKRIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKAGE AFTER MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL CANCER-A PROS8
44. LONG-TERM OUTCOMES OF PERORAL ENDOSCOPIC MYOTOMY FOR PATIENTS WITH ACHALASIA: A SINGLE-CENTRE STUDY8
Ki-67 overexpression for risk stratification of early dysplasia in Barrett’s esophagus: Friend or foe?8
487. THE OUTCOME OF NIVOLUMAB THERAPY FOR PLATINUM-RESISTANT UNRESECTABLE ADVANCED OR RECURRENT ESOPHAGEAL CANCER8
498. LATROGENIC ESOPHAGEAL DISEASE POST OBESITY TREATMENT: SEVERE ESOPHAGEAL DILATATION RELATED TO ADJUSTABLE GASTRIC BANDING (AGB)8
466. ROBOT-ASSISTED CERVICAL ESOPHAGECTOMY (RACE) FOR ESOPHAGEAL CANCER: THE FIRST TWO CASES OF AN ITALIAN HIGH-VOLUME CENTER8
378. LAPAROSCOPIC PRIMARY CLOSURE OF ESOPHAGEAL RUPTURE CAUSED BY BALLOON DILATATION FOR ACHALASIA AND HELLER'S MYOTOMY WITH DOR FUNDOPLICATION8
259. ROBOTIC ESOPHAGECTOMY AND THREE FIELD LYMPHADENECTOMY WITH INTRA-OPERATIVE RECURRENT LARYNGEAL NERVE MONITORING8
189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD8
611. THE UTILITY OF H ANASTOMOSIS IN INFLATABLE MEDIASTINOSCOPE-ASSISTED TRANSHIATAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER8
34. EXTENDED RIGHT THORACIC APPROACH COMPARED WITH LIMITED LEFT THORACIC APPROACH FOR ESOPHAGEAL CANCER: TEN-YEAR SURVIVAL OF A PROSPECTIVE RANDOMIZED TRIAL8
255. EARLY COST-EFFECTIVENESS MODELLING STUDY COMPARING MINIMALLY INVASIVE TRANSCERVICAL ESOPHAGECTOMY (MICE) AND TRANSTHORACIC MINIMALLY INVASIVE ESOPHAGECTOMY (TMIE) IN OESOPHAGEAL CANCER PATIENTS8
Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study7
489. EVALUATION OF THE ONCOLOGICAL QUALITY OF MINIMALLY INVASIVE TRANSCERVICAL OESOPHAGECTOMY (MICE) USING A CADAVERIC MODEL7
599. ASSESSMENT OF BREATHING MECHANICS IN OESOPHAGEAL CANCER SURVIVORS USING A 3D-MOTION CAPTURE SYSTEM7
326. SPONTANEOUS OESOPHAGEAL PERFORATION TREATED WITH OESOPHAGEAL STENT7
478. ENDOSCOPIC RESECTION OF A HUGE ESOPHAGEAL LIPOSARCOMA WITH LIGASURE INSTRUMENT7
278. SHORT- AND LONG-TERM OUTCOME AFTER UPFRONT SURGERY OR NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY IN ELDERLY PATIENTS WITH RESECTABLE ESOPHAGEAL CANCER7
Feeding gastrostomy and duodenostomy using the round ligament of the liver versus conventional feeding jejunostomy after esophagectomy: a meta-analysis7
In vitro and in vivo evaluation of a novel wired transmission pH-combined photographic catheter for ambulatory gastroesophageal reflux monitoring (with videos)7
Omission of intraoperative pyloric procedures in minimally invasive esophagectomy: assessing the impact on patients7
600. DETECTION OF ANASTOMOTIC LEAK THROUGH THE VALUE OF DRAIN FLUID AMYLASE7
457. EVALUATING THE ACCURACY OF CLINICAL SIEWERT CLASSIFICATION, A RETROSPECTIVE REVIEW OF 807 PATIENTS7
178. OUTCOME OF DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL COMBINATION CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER6
777. COMBINED OESOPHAGEAL AND AIRWAY STENTING FOR MALIGNANT OESOPHAGEAL STRICTURES: THE UK’S LARGEST TERTIARY CENTRE EXPERIENCE AND DEVELOPMENT OF A NOVEL ALGORITHM6
372. ASSESSMENT OF TUMOR REGRESSION GRADE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER CHEMORADIOTHERAPY: COMPARISON OF 3 COMMONLY USED SCORING SYSTEMS6
307. INGENUITY OF ESOPHAGOGASTRIC ANASTOMOSIS IN OUR DEPARTMENT -RECONSTRUCTED GASTRIC TUBE STUMP CLOSURE USING ENDO GIA RADIAL RELOAD6
472. ROUTINE PLACEMENT OF FEEDING TUBES SHOULD BE AVOIDED IN ESOPHAGEAL CANCER PATIENTS UNDERGOING SURGERY6
421. UNVEILING THE COMPLEXITY—DISSECTION OF 106 LYMPH NODES IN ESOPHAGEAL CANCER6
Magnetic sphincter augmentation and high-resolution manometry: impact of biomechanical properties on esophageal motility and clinical significance for selection and outcomes6
502. CORRELATION OF LYMPH NODE SIZE WITH METASTATIC INVOLVEMENT IN PATIENTS WITH OESOPHAGEAL CANCER6
795. REVIEW OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA6
406. EXPLORING THE OPTIMAL TIMING OF MINIMALLY INVASIVE SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY6
273. PERIOPERATIVE BLOOD TRANSFUSIONS AND SURVIVAL IN GASTROESOPHAGEAL CANCERS – A SWEDISH POPULATION-BASED STUDY6
632. CAN CARDIOPULMONARY EXERCISE TESTING PREDICT NEOADJUVANT CHEMOTHERAPY TOXICITY IN OESOPHAGEAL ADENOCARCINOMA PATIENTS?6
420. MESH REINFORCEMENT IN HIATAL HERNIA REPAIR: CLINICAL RESULTS OF OUR EARLY EXPERIENCE6
516. MICRONUTRIENT DEFICIENCIES AFTER GASTROESOPHAGEAL CANCER SURGERY6
619. THE STRATEGY OF THE SURGICAL TREATMENT FOR ESOPHAGEAL NEUROENDOCRINE CARCINOMA6
101. INITIAL EXPERIENCE WITH UNDERWATER PERORAL ENDOSCOPIC MYOTOMY (U-POEM) IN THE TREATMENT OF ACHALASIA AT TAM ANH HOSPITAL, HO CHI MINH5
556. PREDICTORS OF EARLY RECURRENCE AFTER OESOPHAGECTOMY AND NEOADJUVANT FLOT5
441. COMBINING LARYNGEAL ULTRASONOGRAPHY (LUSG) WITH VOICE ASSESSMENT OR INTRA-OPERATIVE NERVE MONITORING RESULTS ACCURATELY CONFIRMS NORMAL VOCAL CORD FUNCTION AFTER ESOPHAGECTOMY5
451. PREDICTIVE FACTORS FOR PNEUMONIA AND ANASTOMOTIC LEAK AFTER TRANSTHORACIC ESOPHAGECTOMY FOR CANCER AND FAILURE TO RESCUE ANALYSIS ON 1355 PATIENTS5
What is the significance of the Hill classification?5
383. LOSS OF PERISTALTIC RESERVE DETERMINED BY MULTIPLE RAPID SWALLOWS CORRELATES WITH DYSPHAGIA AND POOR BOLUS TRANSIT IN INEFFECTIVE ESOPHAGEAL MOTILITY5
172. STRATEGY OF SALVAGE ESOPHAGECTOMY AFTER DEFINITIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
446. EFFECT OF PANCREATIC JUICE AND BILE REFLUX TO THE DEVELOPMENT OF ESOPHAGEAL CARCINOGENESIS IN RAT MODEL5
Performance of radiomics-based artificial intelligence systems in the diagnosis and prediction of treatment response and survival in esophageal cancer: a systematic review and meta-analysis of diagnos5
Management and outcomes in a consecutive series of patients with aero-digestive fistula at a tertiary gastro-esophageal surgery center5
247. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA5
228. THORACOACROMIAL ARTERY PERFORATOR FLAP REPAIR OF ACQUIRED INTRATHORACIC NONMALIGNANT TRACHEOESOPHAGEAL FISTULAS THROUGH A MIDSTERNAL INCISION APPROACH5
222. ARE GASTRIC MAPPING BIOPSIES NECESSARY TO DETERMINE THE DISTAL RESECTION MARGIN FOR SIGNET RING ADENOCARCINOMAS OF THE OESOPHAGO-GASTRIC JUNCTION?5
427. CAN WE OPTIMIZE THE RECOMMENDATIONS FOR FOLLOW-UP OF BARRETT’S ESOPHAGUS THROUGH CRITICAL ANALYSIS OF RISK FACTORS IN A SPECIFIC POPULATION?5
256. PROGNOSIS AND RISK FACTORS FOR SUPRACLAVICULAR LYMPH NODE METASTASIS IN PATIENTS WITH MIDDLE AND LOWER THORACIC ESOPHAGEAL CANCER5
Gastroesophageal reflux disease following laparoscopic vertical sleeve gastrectomy and laparoscopic roux-en-Y gastric bypass: meta-analysis and systematic review of 5-year data5
330. RIGHT DIAPHRAGMATIC HERNIA FOLLOWING PARA OESOPHAGEAL HERNIA REPAIR5
463. PREOPERATIVE ASSESSMENT USING A SCORING SYSTEM AFTER NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL FOR LOCALLY ADVANCED ESOPHAGEAL CANCER5
260. RECURRENT EROSIVE ESOPHAGITIS AFTER SURGICAL TREATMENT IN DIFFERENT TYPE OF ACHALASIA5
605. NEOADJUVANT FLOT FOR LOCALLY ADVANCED ESOPHAGEAL CANCERS: A SYSTEMATIC REVIEW AND META-ANALYSIS5
030. PROGNOSTIC SIGNIFICANCE OF LOW HER2 EXPRESSION IN ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION: A RETROSPECTIVE ANALYSIS5
210. DEVELOPMENT OF NOVEL IMMUNOTHERAPY-BASED THERAPIES IN OESOPHAGEAL ADENOCARCINOMA BY HARNESSING TUMOUR NEOANTIGENS5
269. LARGE CELL NEUROENDOCRINE CARCINOMA OF THE OESOPHAGUS: A RARE ENTITY. SYSTEMATIC REVIEW OF THE LITERATURE IN REGARDS TO ITS MANAGEMENT5
478. OVERVIEW ON USE OF THE TRANSCERVICAL MEDIASTINOSCOPIC APPROACH FOR MINIMALLY INVASIVE TREATMENT OF ESOPHAGEAL CANCER: ESTABLISHMENT OF INTERNATIONAL COLLABORATIVE GROUP5
534. EVALUATION OF SURGICAL OUTCOMES IN ROBOTIC-ASSISTED ESOPHAGECTOMY5
213. A NEW MANOMETRIC TOOL TO EVALUATE THE EFFICACY OF LAPAROSCOPIC ANTIREFLUX SURGERY5
Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett’s esophagus: a long-term analysis5
104. RISK FACTORS FOR ANASTOMOTIC LEAKAGE AFTER ESOPHAGEAL SUBTOTAL RESECTION AND GASTRIC TUBE RECONSTRUCTION U USING ICG FLUORESCENCE5
457. A CASE OF ADVANCED ESOPHAGEAL CANCER WITH SITUS INVERSUS TOTALIS SUCCESSFULLY TREATED WITH THORACOSCOPIC SUBTOTAL ESOPHAGECTOMY5
Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities5
Safety, efficacy, and cost-effectiveness of minimally invasive esophagectomies versus open esophagectomies: an umbrella review5
417. ROBOT-ASSISTED MINIMALLY INVASIVE ESOPHAGECTOMY WITH UPPER MEDIASTINAL LYMPHADENECTOMY5
342. GENOMIC ANALYSIS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN OESOPHAGEAL ADENOCARCINOMA4
289. RISK FACTOR OF RELAPSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO ACHIEVE PATHOLOGIC COMPLETE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY4
236. INDOCYANINE GREEN TRACHEOBRONCHIAL FLUORESCENCE (ICG-TBF) VIA NEBULIZATION DURING MINIMALLY INVASIVE ESOPHAGECTOMY -A NOVEL TECHNIQUE4
143. NEOADJUVANT CHEMORADIOTHERAPY VERSUS CHEMOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTER ENSURE STUDY4
604. REAL-WORLD MANAGEMENT AND OUTCOMES OF PATIENTS WITH NON METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN THE FREGAT DATABASE4
177. BULKY LYMPHADENOPATHY IN ESOPHAGEAL CANCER: ASSESSING PATHOLOGICAL AND SURVIVAL OUTCOMES AFTER TREATMENT WITH CURATIVE INTENT4
600. TREATMENT OUTCOME OF CLINICALLY UNRESECTABLE ESOPHAGEAL CANCER AFTER NEO-ADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL4
439. ACUTE GASTRIC VOLVULUS—LATE OCCURRENCE AFTER HIATAL HERNIA REPAIR WITH MESH4
406. A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE USE OF ARTIFICIAL INTELLIGENCE IN THE ENDOSCOPIC DIAGNOSIS OF ESOPHAGEAL CANCER4
272. IMPLEMENTATION OF AN ERAS PROTOCOL IN PATIENTS UNDERGOING ESOPHAGECTOMY: EVALUATION OF THE RESULTS4
296. A BEGINNER’S THREE-YEAR LEARNING CURVE WITH ESOPHAGECTOMIES: A STUDY FROM A PERIPHERAL CANCER CENTRE IN NORTH-EAST INDIA4
410. THE RELATIONSHIP BETWEEN GASTRIC CONDUIT EMPTYING, FUNCTIONAL ANATOMY AND PERISTALSIS: A DETAILED ANALYSIS USING DYNAMIC MAGNETIC RESONANCE IMAGING4
184. INTRATHORACIC SIDE-OVERLAP ESOPHAGOGASTROSTOMY DURING MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGOGASTRIC JUNCTION CANCER4
515. EXOCRINE PANCREATIC FUNCTION IN PATIENTS AFTER ESOPHAGECTOMY; IS TREATMENT WITH PANCREATIC ENZYMES NECESSARY?4
474. MANOMETRIC IDENTIKIT OF A FUNCTIONING AND EFFECTIVE FUNDOPLICATION IN THE HIGH-RESOLUTION MANOMETRY ERA4
Magnetic sphincter augmentation: considerations for use in Barrett’s esophagus4
303. A NOVEL ‘WATERFALL METHOD’ OF FILLING THE POSTERIOR MEDIASTINAL CAVITY AFTER ESOPHAGECTOMY USING OMENTAL FLAP IN RETROSTERNAL GASTRIC TUBE RECONSTRUCTION4
380. INTEGRATIVE TRANSCRIPTOMIC AND FUNCTIONAL ANALYSIS OF CHEMOTHERAPY RESISTANCE IN ESOPHAGEAL ADENOCARCINOMA4
496. OESOPHAGEAL STENTING IN BOERHAAVE SYNDROME: OUR EXPERIENCE4
260. EFFECT OF ENDOLUMINAL VACUUM THERAPY ON THE PERFUSION OF GASTRIC CONDUIT IN A PORCINE MODEL FOR ESOPHAGECTOMY4
303. THE TISSUE SYSTEMS PATHOLOGY-9 TEST PROVIDES CLINICALLY-IMPACTFUL RISK STRATIFICATION IN PATIENTS WITH BARRETT’S ESOPHAGUS: CLINICAL EXPERIENCE IN A MULTICENTER COHORT4
243. IS MUCOSAL CHANGE IN COELIAC DISEASE RESTRICTED TO SMALL BOWEL? STUDY OF OESOPHAGEAL MUCOSAL CHANGES IN CHILDREN WITH COELIAC DISEASE4
549. CLINICAL IMPLICATIONS OF SELECTIVE RIGHT PARATRACHEAL LYMPH NODE DISSECTION IN PATIENTS WITH EARLY-STAGE ESOPHAGEAL CANCER: PROPENSITY-SCORE MATCHED ANAYLSIS4
333. TECHNICAL CONSIDERATIONS IN UPPER-GI RECONSTRUCTION – A CASE SERIES4
549. LAPAROSCOPIC CARDIOPLASTY FOR FAILED PRIMARY TREATMENT OF ACHALASIA4
557. POTENTIAL THERAPEUTIC TARGETS OF TRPV2 AND SLC12A2 IN ESOPHAGEAL ADENOCARCINOMA CANCER STEM CELLS4
010. UTILITY OF ROBOTIC-ASSISTED ESOPHAGECTOMY FOR ESOPHAGEAL CANCER BASED ON LONG-TERM SURVIVAL: A PROPENSITY SCORE ANALYSIS COMPARED WITH THORACOSCOPIC SURGERY3
328. DEVELOPMENT OF A MACHINE LEARNING-BASED PROGRAMMED CELL DEATH GENES PROGNOSTIC MODEL FOR ESOPHAGEAL CARCINOMA3
023. CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY FOLLOWED BY SALVAGE LYMPHADENECTOMY FOR RECURRENCE IN CERVICAL LYMPH NODES AFTER ESOPHAGECTOMY: A SINGLE-CENTER PROSPECTIVE STUDY3
252. ACCURACY OF PREDICTING RESIDUAL DISEASE AND DISEASE PROGRESSION DURING ACTIVE SURVEILLANCE FOR ESOPHAGEAL CANCER3
807. A REVISED APPROACH TO THE ESOPHAGOGASTRIC JUNCTION: A MODIFIED SIEWERT CLASSIFICATION3
The risk of autism spectrum disorder and intellectual disability but not attention deficit/hyperactivity disorder is increased in individuals with esophageal atresia3
A systematic review of hiatus hernia classifications3
Sex differences in survival following surgery for esophageal cancer: A systematic review and meta-analysis3
265. THE COST-EFFECTIVENESS OF RISK-BASED MANAGEMENT OF BARRETT’S ESOPHAGUS PATIENTS USING TISSUECYPHER OR P53 BIOMARKERS: A MICROSIMULATION STUDY3
143. LONG-TERM DYSPHAGIA AND REGURGITATION IN 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS: PREVALENCE, CORRELATES, AND PREDICTIVE MODELS IN A MULTI-CENTER COHORT3
317. WHAT IS THE APPROPRIATE TREATMENT STRATEGY FOR SUPERFICIAL ESOPHAGEAL CANCER WITH SYNCHRONIZED HEAD AND NECK CANCER?3
326. REDUCTION OF ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY WITH RETROSTERNAL GASTRIC TUBE RECONSTRUCTION3
Re-thinking routine critical care admission after esophagectomy3
Is proton-pump inhibitor effective in preventing postoperative bleeding after esophageal endoscopic submucosal dissection?3
Comparing clinical outcomes of peroral endoscopic myotomy for achalasia between Eastern and Western countries: a systematic review and meta-analysis3
286. TREATMENT WITH CURATIVE INTENT FOR OLIGOMETASTATIC GASTROESOPHAGEAL CANCER-RESULTS OF A PROSPECTIVE MULTICENTER STUDY3
Is systematic formal crural repair mandatory at the time of magnetic sphincter augmentation implantation?3
241. EVALUATION OF THE PYLORUS FOLLOWING GASTRIC CONDUIT RECONSTRUCTION IN OESOPHAGECTOMY USING IMPEDANCE PLANIMETRY—A SYSTEMATIC REVIEW WITH META-ANALYSIS3
456. THE USEFULNESS OF NEOADJUVANT CHEMOTHERAPY FOR SIEWERT TYPE II EGJ ADENOCARCINOMA3
149. DOES PSEUDO-LYMPH NODE SKIP METASTASIS AFTER NEOADJUVANT THERAPY AFFECT ESOPHAGEAL SQUAMOUS CELL CARCINOMA OUTCOMES?—A MULTICENTER STUDY3
262. THE NUMBER OF CAJAL CELLS IN MUSCLE LAYER OF THE ESOPHAGUS IN PATIENTS WITH ACHALASIA3
Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study3
Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis3
430. PROGNOSTIC PATTERNS OF LYMPH NODES WITH COMPLETE TREATMENT RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT CHEMOTHERAPY3
Management of esophageal anastomotic leaks, a systematic review and network meta-analysis3
Research gap in esophageal achalasia: a narrative review3
Sex- and gender-specific differences in symptoms and health-related quality of life among patients with gastroesophageal reflux disease3
754. PATHOLOGICAL RESPONSE PREDICTS EFFICACY OF ADJUVANT FLOT CHEMOTHERAPY IN GASTROESOPHAGEAL CANCER: AN INTERNATIONAL COHORT STUDY3
305. GASTROESOPHAGEAL REFLUX DISEASE IN LUNG TRANSPLANT RECIPIENTS IN ASIA3
134. MEDIASTINOSCOPIC ESOPHAGECTOMY AS A VIABLE APPROACH FOR ESOPHAGEAL PERFORATION: A 10-CASE REVIEW2
415. A WEBCAST FOR THE EDUCATION AND INFORMATION OF PATIENTS WITH BARRETT’S ESOPHAGUS AND BARRETT’S CANCER2
460. INITIAL EXPERIENCE OF MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AS A GASTROINTESTINAL SURGEON2
087. LAPAROSCOPIC MEDIASTINAL APPROACH TO TOTAL GASTRIC TUBE RESECTION FOR GASTRIC TUBE CANCER THROUGH A RETROSTERNAL ROUTE2
227. RELATIONSHIP BETWEEN 90-DAY PROGNOSIS NUTRITIONAL INDEX AND INFLAMMATORY RESPONSE MARKERS AND LONG-TERM SURVIVAL IN ESOPHAGEAL CANCER2
364. IMPROVING PRE-OPERATIVE EMOTIONAL DISTRESS SHORTENS HOSPITALIZATION FOR ESOPHAGECTOMY2
368. THE ROLE OF PG-SGA SCORE IN PREDICTING SHORT- TERM POSTOPERATIVE COMPLICATIONS IN ESOPHAGEAL CANCER SURGERY2
212. MANAGEMENT OF CT2N0M0 ESOPHAGEAL CANCER: A PROTOCOL FOR SYSTEMATIC REVIEW AND CLINICAL PRACTICE GUIDELINES2
166. ROBOTIC-ASSISTED BILATERAL EPIPHRENIC DIVERTICULECTOMY WITH HELLER MYOTOMY AND DOR FUNDOPLICATION: A SURGICAL TECHNIQUE2
344. SURGICAL APPROACH FOR SPONTANEOUS ESOPHAGEAL RUPTURE: THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY2
167. LYMPHATIC INVASION CAN PREDICT POSTOPERATIVE LYMPH NODE RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2
202. THE INFLUENCE OF SOCIOECONOMIC DISADVANTAGE ON SHORT- AND LONG-TERM OUTCOMES AFTER OESOPHAGECTOMY FOR CANCER: AN AUSTRALIAN MULTICENTRE STUDY2
115. EVALUATING BODY MASS INDEX IN SURVIVAL AND COMPLICATIONS OF OLDER OESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER ESOPHAGECTOMY: A PROPENSITY SCORE ANALYSIS2
Neoadjuvant or perioperative treatment in resectable esophageal adenocarcinoma beyond ESOPEC: tailoring FLOT or CROSS2
Impact of aspirin use on rates of metastasis in patients with esophageal cancer: insights from the National Inpatient Sample2
227. CAUSES OF IN-HOSPITAL MORTALITY FOLLOWING TRANSTHORACIC ESOPHAGECTOMY FOR CANCER2
Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes2
448. EFFECTS OF DIFFERENT ANALGESIC MODALITIES ON PAIN RELIEF AND SAFETY AFTER MINIMALLY INVASIVE ESOPHAGECTOMY: A RANDOMIZED CONTROLLED CLINICAL STUDY2
479. MINIMALLY INVASIVE OESOPHAGECTOMY VS. OPEN: SHORT-TERM RESULTS2
645. CLINICAL SIGNIFICANCE OF LOCAL TREATMENT FOR RECURRENCE WITHIN THE SURGICAL FIELD AFTER RADICAL ESOPHAGECTOMY2
343. TEXTBOOK OUTCOMES OF ESOPHAGECTOMIES FROM A LOW VOLUME CANCER CENTRE IN INDIA2
552. LAPAROSCOPIC RE DO FUNDOPLICATION2
Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis2
537. ASSESSING THE EFFECT OF HIATAL HERNIA SIZE ON PERIOPERATIVE OUTCOMES AND HOSPITAL READMISSION RATES AFTER PRIMARY REPAIR2
737. ETHNIC, GENDER AND TUMOR-SPECIFIC ASSESSMENT OF BODY COMPOSITION IS CRITICAL FOR CLINICAL RELEVANCE IN PATIENTS UNDERGOING THERAPY FOR ESOPHAGEAL2
138. MULTI-CENTER CLINICAL ANALYSIS AND SINGLE-CELL SEQUENCING INSIGHTS INTO THE DEVELOPMENTAL MECHANISMS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA2
499. ICG GUIDED THORACIC DUCT CLIPPING FOR CHYLE LEAKS2
330. RANDOMIZED PHASE II STUDY OF DOCETAXEL VERSUS PACLITAXEL IN PATIENTS WITH ESOPHAGEAL SCC REFRACTORY TO FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY: OGSG12012
Clinical effect of home enteral tube feeding supplementation on nutritional status after esophagectomy with retrosternal gastric tube reconstruction2
378. FLOT VS ECX: A COMPARISON OF TWO NEOADJUVANT CHEMOTHERAPY REGIMEN’S EFFECTS ON SARCOPENIA IN ESOPHAGOGASTRIC ADENOCARCINOMA PATIENTS2
484. OESOPHAGECTOMY FOR CANCER: BEARING ON PATIENTS’ CHOICES2
011. OUR SURGICAL TECHNIQUE OF COMBINED RESECTION WITH AORTIC ADVENTITIA USING DA VINCI XI FOR ESOPHAGEAL CANCER INVADING DESCENDING AORTA2
Results of the ARROW survey of anti-reflux practice in the United Kingdom2
414. ILEOCOLON GRAFT VS GASTRIC CONDUIT IN ESOPHAGEAL RECONSTRUCTION FOR ESOPHAGEAL CANCER: ENHANCED QUALITY OF LIFE WITH COMPARABLE SURVIVAL OUTCOMES2
Single-center experience in implementation of endoscopic surveillance protocol after esophagectomy2
248. PLEURAL MONITORING FOR ANASTOMOTIC LEAKAGE AFTER TRANSTHORACIC ESOPHAGECTOMY FOR CANCER WITH LACTATE, LACTATE DEHYDROGENASE, AMYLASE, AND GLUCOSE2
244. A NOVEL SERUM GLYCOPROTEIN BIOMARKER PANEL FOR SCREENING OF ESOPHAGEAL ADENOCARCINOMA AND SURVEILLANCE OF BARRETT’S ESOPHAGUS2
509. DOES SARCOPENIA AFFECT THE OUTCOME OF PATIENTS WITH ESOPHAGEAL CARCINOMA AFTER ESOPHAGECTOMY?2
335. LONG TERM RISK FOR PROGRESSION TO NEOPLASIA FOR BARRETT’S ESOPHAGUS PATIENTS WITH VALIDATED LOW-GRADE DYSPLASIA OR INDEFINITE FOR DYSPLASIA2
453. THE EFFECTIVITY OF NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL ADENOCARCINOMA WITH PRESENCE OF EXTRACELLULAR MUCINE, SIGNET-RING CELLS OR POORLY COHESIVE CELLS2
263. CLINICAL PRESENTATION, DIAGNOSIS AND MANAGEMENT OF EARLY, AVERAGE AND LATE ONSET ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY2
International Society for Diseases of the Esophagus consensus on management of the failed fundoplication2
The accuracy of hospital acquired pneumonia diagnosis following esophagectomy: a retrospective analysis from a tertiary specialist centre2
397. LEFT PILLAR PINCHING TECHNIQUE FOR MINIMALLY INVASIVE REPAIR OF PARA-CONDUIT HERNIA1
246. SPATIAL HETEROGENEITY OF PD-L1 EXPRESSION INFLUENCE ITS ASSESSMENT IN ESOPHAGEAL SQUAMOUS CARCINOMA (ESCC)1
154. EVALUATION OF BLOOD FLOW IN RECONSTRUCTED GASTRIC TUBE AND IDENTIFICATION OF OPTIMAL ANASTOMOSES IN ESOPHAGECTOMY1
494. GIANT GASTROINTESTINAL STROMAL TUMOR OF THE ESOPHAGUS: REPORT OF TWO CASES1
267. IDENTIFYING CANCER-ASSOCIATED FIBROBLAST POPULATIONS DRIVING THERAPY RESISTANCE IN GASTROESOPHAGEAL ADENOCARCINOMA1
453. TREATMENT AND SURVIVAL OF PATIENTS WITH A POSITIVE RESECTION MARGIN AFTER NEOADJUVANT CHEMORADIOTHERAPY AND ESOPHAGECTOMY1
144. OPTIMIZING MEDIASTINAL ACCESS FOR RADICAL ESOPHAGECTOMY: A BILATERAL CERVICAL AND TRANSHIATAL APPROACH TO RESECT ESOPHAGEAL CANCER1
18. REFLUX OF DUODENAL CONTENTS INDUCES ESOPHAGEAL CARCINOGENESIS (SCC, ADC)1
261. CONVERSION ESOPHAGECTOMY FOR CT4B ESOPHAGEAL CANCER - MIE VS OPEN -1
365. METHYLATION BIOMARKERS TO STRATIFY BARRETT’S ESOPHAGUS PATIENTS PROGRESSING AND NON-PROGRESSING TO ESOPHAGEAL ADENOCARCINOMA1
399. CURRENT PRACTICE IN ANTIREFLUX AND HIATAL HERNIA SURGERY: EXPLORATION OF THE BELGIAN FIELD1
Criteria of patient selection for magnetic sphincter augmentation1
309. SURGICAL TREATMENT FOR THE RECURRENT SITE OF ESOPHAGEAL CANCER AFTER ESOPHAGECTOMY1
623. A NEW PROGNOSTIC EVALUATION OF POSTOPERATIVE ESOPHAGEAL CANCER: LONG-TERM FLAIL INVESTIGATION1
766. LASTING SYMPTOMS AFTER OESOPHAGEAL RESECTIONAL SURGERY (LASORS): MULTICENTRE VALIDATION COHORT STUDY1
254. QUANTIFYING PERIOPERATIVE RISKS FOR ANTIREFLUX AND HIATUS HERNIA SURGERY: A MULTICENTER COHORT STUDY OF 4301 PATIENTS1
152. THE PROGNOSTIC IMPACT OF PARA-RECURRENT LARYNGEAL NERVE LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE COHORT STUDY1
330. PRE-EMPTIVE ENDOLUMINAL VACUUM THERAPY WITH A SURGICAL DRAIN FOR REDUCTION OF ANASTOMOTIC LEAK RATE FOLLOWING MINIMALLY INVASIVE ESOPHAGECTOMY1
564. PRONE POSITION THORACOSCOPIC HAND-SEWN ESOPHAGO-GASTRIC ANASTOMOSIS DURING 2-STAGE TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER. SURGICAL TECHNIQUE1
137. THE COMPARISON OF SHORT-TERM OUTCOMES BETWEEN NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY AND NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CANCER1
370. LOWER MEDIASTINUM DISSECTION IN THORACOSCOPIC ESOPHAGECTOMY1
430. MAPPING OF LYMPH NODE METASTASIS FROM ESCC AFTER NEOADJUVANT TREATMENT: A PROSPECTIVE ANALYSIS FROM A HIGH-VOLUME INSTITUTION IN CHINA1
Predictors of enteral tube dependence in pediatric esophageal atresia1
211. POSTOPERATIVE TACHYARRHYTHMIA IN ESOPHAGEAL CANCER SURGERY WITH PRESERVING AZYGOS VEIN ARCH1
290. EVALUATION OF THE POST-OPERATIVE GERD AND RESIDUAL CHEST PAIN AFTER POEM1
571. ESOPHAGEAL PERFORATION AFTER LOBECTOMY: PADLOCK CLIP TO THE RESCUE1
296. CLINICAL T1B-SM2-3N0M0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
222. LONG-TERM SURVIVAL OF ROBOT-ASSISTED ESOPHAGECTOMY AND ITS UTILITY IN TREATING CT4B ESOPHAGEAL CANCER1
449. CAN LARGE ANASTOMOTIC LEAKAGE AFTER ESOPHAGEAL SURGERY BE TREATED BY ENDOLUMINAL VACUUM-ASSISTED CLOSURE (EVAC THERAPY)?: A CASE REPORT1
275. PREOPERATIVE 3D-CT EVALUATION OF THE BRONCHIAL ARTERIES IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER1
385. TRANSLATING MOLECULAR-TARGETING FLUORESCENT PROBES IN OESOPHAGEAL CANCER PRE-CLINICAL MODELS1
0.18378806114197